Bleomycin

Glycopeptide AntibioticRx: PrescriptionCompound: Approved

Also known as: BLE, Blenoxane, Bleo, Bleomycin A2, Bleomycin B2, Bleomycin sulfate, BLM

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Bleomycin at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Bleomycin is a glycopeptide antibiotic used as a chemotherapeutic agent for several malignancies; it induces DNA breaks and is limited by dose‑related pulmonary toxicity.

Mechanism of Action

DNA strand scission via Fe(II)-mediated generation of free radicals causing oxidative damage and cell death

Routes of Administration

IntralesionalIntramuscularIntrapleuralIntravenousSubcutaneous

Goals & Uses

  • Testicular germ cell tumor treatmentOncologyHigh
  • Testicular cancerOncologyHigh
  • Ovarian germ cell tumor treatmentOncologyModerate
  • Hodgkin lymphoma treatmentOncologyHigh
  • Cutaneous warts (off‑label)DermatologyLow
  • Squamous cell carcinoma of head & neckOncologyModerate
  • Squamous cell carcinoma treatmentOncologyModerate
  • Malignant pleural effusionOncologyModerate
  • Malignant pleural effusion sclerotherapyPalliative OncologyModerate
  • Hodgkin lymphomaOncologyHigh
  • Non-Hodgkin lymphoma treatmentOncologyModerate

Contraindications

  • Severe pulmonary diseaseRespiratoryHigh
  • Severe renal impairment (creatinine clearance <30 mL/min)RenalModerate
  • Prior severe bleomycin pulmonary toxicityDrug Toxicity HistoryHigh
  • Severe renal impairmentOrganModerateKidney function concerns
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Hypersensitivity to bleomycinAllergy/immunologyHigh
  • Cumulative dose >400 unitsOncology/safetyHigh
  • Pre‑existing pulmonary fibrosisRespiratoryHigh
  • High‑concentration oxygen therapy (>30% FiO2)RespiratoryHigh

Adverse Effects

  • Skin rash / hyperpigmentationDermatologicCommon
  • AlopeciaDermatologicUncommonHair loss
  • Cutaneous toxicity (skin thickening, hyperpigmentation, alopecia)DermatologicCommon
  • Pulmonary fibrosis/pneumonitisRespiratoryUncommon
  • Nausea/vomitingGastrointestinalCommon
  • Fever and chillsConstitutionalCommon
  • Nausea and vomitingGastrointestinalCommon
  • MucositisGastrointestinal / MucosalUncommon
  • MyelosuppressionHematologicUncommon
  • Anaphylactoid/idiosyncratic reactionsImmunologicUncommon
  • Pulmonary fibrosisPulmonaryCommon

Drug Interactions

  • Radiation therapyHigh
  • AmiodaroneModerate
  • Supplemental oxygen (high FiO2)High
  • DigoxinLow
  • PhenytoinModerate
  • G‑CSF (filgrastim)Moderate
  • CisplatinModerate
  • Granulocyte colony-stimulating factors (G-CSF)Moderate
  • High inspired oxygenHigh

Population Constraints

  • SmokersLifestyleRelative
  • Patients with chronic lung diseaseRespiratoryRelative
  • Renal impairmentOrgan ImpairmentRelative
  • Elderly patients (≥70 years)AgeRelative
  • Patients undergoing general anesthesiaPerioperativeRelative
  • Children (<12 y)PediatricRelative
  • Elderly (>70 y)GeriatricRelative
  • Patients with renal impairmentOrgan ImpairmentRelative
  • Pregnant womenReproductiveAbsolute

Regulatory Status

  • European UnionApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinomaEMA approval; same safety concerns
  • United StatesApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinoma of head and neck, Malignant pleural effusionFDA‑approved; boxed warning for pulmonary toxicity
  • United KingdomApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinomaMHRA approval; used under specialist supervision

Approved for Hodgkin lymphoma, testicular cancer, and squamous cell carcinoma; contraindicated in patients with pre‑existing pulmonary fibrosis and during high‑concentration oxygen therapy due to risk of severe lung injury.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Bleomycin?

Bleomycin is a glycopeptide antibiotic used as a chemotherapeutic agent for several malignancies; it induces DNA breaks and is limited by dose‑related pulmonary toxicity.

What is Bleomycin used for?

Bleomycin is educationally associated with: Testicular germ cell tumor treatment, Testicular cancer, Ovarian germ cell tumor treatment, Hodgkin lymphoma treatment, Cutaneous warts (off‑label), Squamous cell carcinoma of head & neck, Squamous cell carcinoma treatment, Malignant pleural effusion, Malignant pleural effusion sclerotherapy, Hodgkin lymphoma, Non-Hodgkin lymphoma treatment. Educational only — not medical advice.

How is Bleomycin administered?

Recorded routes of administration: Intralesional, Intramuscular, Intrapleural, Intravenous, Subcutaneous.

What are the potential side effects of Bleomycin?

Reported adverse effects include: Skin rash / hyperpigmentation, Alopecia, Cutaneous toxicity (skin thickening, hyperpigmentation, alopecia), Pulmonary fibrosis/pneumonitis, Nausea/vomiting, Fever and chills, Nausea and vomiting, Mucositis, Myelosuppression, Anaphylactoid/idiosyncratic reactions, Pulmonary fibrosis. This list is not exhaustive — consult a qualified clinician.

Who should avoid Bleomycin?

Recorded contraindications: Severe pulmonary disease, Severe renal impairment (creatinine clearance <30 mL/min), Prior severe bleomycin pulmonary toxicity, Severe renal impairment, Pregnancy, Hypersensitivity to bleomycin, Cumulative dose >400 units, Pre‑existing pulmonary fibrosis, High‑concentration oxygen therapy (>30% FiO2). Consult a qualified clinician before use.

More in this class